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Abstract
The introduction of the highly active antiretroviral therapy (HAART) has greatly improved survival. However, these 
treatments fail to definitively cure the patients and unveil the presence of quiescent HIV-1 reservoirs like cells from 
monocyte-macrophage lineage. A purge, or at least a significant reduction of these long lived HIV-1 reservoirs will be 
needed to raise the hope of the viral eradication. This review focuses on the molecular mechanisms responsible for 
viral persistence in cells of the monocyte-macrophage lineage. Controversy on latency and/or cryptic chronic 
replication will be specifically evoked. In addition, since HIV-1 infected monocyte-macrophage cells appear to be more 
resistant to apoptosis, this obstacle to the viral eradication will be discussed. Understanding the intimate mechanisms 
of HIV-1 persistence is a prerequisite to devise new and original therapies aiming to achieve viral eradication.
Introduction
Human immunodeficiency 1 (HIV-1), identified in 1983
[1], remains a global health threat responsible for a
world-wide pandemic. Several advances have been made
in curing acquired immune deficiency syndrome (AIDS)
since the introduction of the highly active antiretroviral
therapy (HAART) in 1996. AIDS pandemic has stabilized
on a global scale in 2008 with an estimated 33 million
people infected worldwide (data from UN, 2008). Even if
an effective AIDS vaccine is still lacking, the introduction
of HAART greatly extended survival. This therapy can
reduce plasma virus levels below detection limits (≤ 50
copies/ml). It induces a biphasic decline of HIV-1 RNA
with a rapid decline of infected CD4+ T cells (half life 0.5
day) followed by a decline originating from infected tissue
macrophages (half life 2 weeks) [2]. However, with very
sensitive methods [3,4], a residual viremia is still detected
in patients on HAART. Moreover, HIV RNA returns to a
m e a s u r a b l e  p l a s m a  l e v e l  i n  l e s s  t h a n  t w o  w e e k s  w h e n
HAART is interrupted [5,6]. These observations suggest
that even long term suppression of HIV-1 replication by
HAART cannot totally eliminate HIV-1, the virus persists
in cellular reservoirs because of viral latency, cryptic
ongoing replication or poor drug penetration [7-9]. In
fact, the persistence of infection is not so surprising since,
from an evolutionary point of view, this is the best form
of adaptation of viruses to the host environment. There
are essentially two theories of persistent infection: latency
and ongoing replication. Latency is best described as a
lack of proviral gene expression. On the other hand,
ongoing replication requires continuous viral expression
without cytopathic effects. It is important to distinguish
between the two possibilities since they call for very dif-
ferent therapeutic interventions. The theory of ongoing
r e p l i c a t i o n  s u g g e s t s  t h a t  d r u g  r e s i s t a n c e  t o  t r e a t m e n t
may develop. In this case treatment intensification and
the design of new anti HIV-1 molecules are needed in the
long term. On the other hand, if viruses are released by
burst from stable reservoirs, multi drug resistance does
not develop, however HAART alone is ineffective. In this
case new strategies are needed to purge the reservoirs,
which in combination with HAART should be able to
eradicate the virus in infected patients.
Resting memory CD4+ T cells are the major cellular
and the best characterized reservoir in the natural host
[7,10-13]. The presence of latent proviral HIV-1 DNA in
this cell population has been undoubtedly proven [10].
But there are other reservoirs. Genetic studies showed
that during rebound viremia (when HAART was inter-
rupted) the virus could be detected from another reser-
voir than the CD4+ T cells [14-16]. It has been proposed
that peripheral blood monocytes, dendritic cells and
macrophages in the lymph nodes and haematopoitic stem
cells in the bone marrow can be infected latently and
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therefore contribute to the viral persistence [17-22]. It is
still debated whether or not viral persistence in these lat-
ter reservoirs is due to true latency or to low level ongo-
ing replication [23,24].
In this review, we focus on the molecular mechanisms
responsible for viral persistence in cells of the monocyte-
macrophage lineage since they are believed to be an
important source of HIV-1 [14,19]. Several features make
cells from this lineage a potential HIV-1 reservoir. Con-
trary to CD4+ T cells, HIV-1 infection is generally not
lytic for these cells [25,26]. The particles produced in
macrophages are budding into intracytoplasmic com-
partments which may represent favored sites for HIV-1
assembly. [27,28] (see also the accompanying review from
Benaroch et al). Mechanisms underlying HIV-1 budding
that involved Gag and the ESCRT pathway, were recently
reviewed [29]. Cells from monocyte-macrophage are also
more resistant to cytopathic effects and they are able to
harbor viruses for a longer period. It may arrive that
infected tissue macrophages, such as microglial cells in
the brain, produce viruses during their total lifespan [30].
Finally, a major obstacle for the eradication of the virus is
that HIV-1 makes infected monocyte-macrophage cells
more resistant to apoptosis. Understanding the intimate
mechanisms underlying HIV-1 persistence in the mono-
cyte-macrophage lineage will be needed to devise new
and original therapies to achieve viral eradication.
Evidence for the constitution of an HIV-1 reservoir 
by cells from the monocyte-macrophage lineage
Cells of myeloid lineage including monocytes, mac-
rophages and dendritic cells (figure 1) play an important
role in the initial infection and therefore contribute to its
pathogenesis throughout the course of infection. This is
mainly because these cells are critical immune cells
responsible for a wide range of both innate and adaptative
immune functions.
Infected monocytes have been recovered from the
blood of HIV-1 infected patients, even from those on
HAART and with a viral load below detectable limits
[19,31]. Early studies have shown that monocytes harbor
latent HIV-1 proviral DNA [32]. Interestingly, a minor
monocyte subset, the CD16+ is more permissive to the
infection than the more abundant CD14++CD16- mono-
cyte subsets [33]. Although HIV-1 proviral DNA is only
in less than 1% of circulating monocytes (between 0.01 to
1%), these cells are important viral reservoirs and are
responsible for the dissemination of HIV-1 into sanctuar-
ies such as the brain [19,23,31,34,35]. Infected circulating
monocytes are also recruited to the gastrointestinal tract.
They later differentiate into macrophages and form the
HIV-1 reservoir of the intestine [36,37]. Some authors
suggest that these cells are not true latent cells, since
monocytes remain in circulation for only up to 3 days and
replication-competent viruses may be recovered from the
blood of patients. They rather suggest that a recent ongo-
ing infection of these cells or their precursors takes place
[ 3 8 ] .  I n  f a v o r  o f  t h i s  s u g g e s t i o n  i s  t h e  v i r a l  e v o l u t i o n
within this compartment [19].
Dendritic cells are also involved in the dissemination of
HIV-1 following primary infection [39]. After capturing
viruses at the site of infection, mature dendritic cells
migrate into lymph nodes where they participate in the
transmission of HIV-1 to CD4+ T cells [40]. Mature
myeloid dendritic cells located in lymph nodes can sus-
tain a very low level virus replication and therefore have a
potential role in HIV-1 latency and/or ongoing replica-
tion. The mechanism of this viral persistence is not yet
known [41-43].
Macrophages harboring the CD4 receptor and CCR5
coreceptor are now recognized as early cellular targets for
HIV-1 [44]. These cells are able to produce and harbor
the virus for a longer period. This is partly due to the
higher resistance of these cells to cytopathic effects. It is
less clear whether macrophages have a role in HIV-1
latency [22,45] or not. In patients on HAART very few
lymph node macrophages are infected (about 0,005%).
However, the finding of in vivo reactivation of these
infected macrophages in response to opportunistic infec-
tions is in favor of macrophages as HIV-1 reservoirs
[46,47]. Finally, resident macrophages of the central ner-
vous system (CNS) deserve attention since they are
involved in the pathogenesis of HIV-1-associated demen-
tia [48,49]. Four types of macrophages were described in
the CNS, the meningeal macrophages, the macrophages
of the choroid-plexus, the perivascular macrophages and
the microglial cells [48]. Among these four types, the
perivascular macrophages and the microglial cells are the
main targets for HIV-1 in the CNS [49]. These cells have a
low turnover, 2-3 months for the perivascular mac-
rophages and several years for the microglial cells. These
features make these cells potential reservoirs for HIV-1
[30,50].
Haematopoïtic cells (HPC) have also been proposed to
serve as a viral reservoir, since a subpopulation of CD34+
HPCs express CD4 and CCR5 and/or CXCR4 and these
cells are susceptible to HIV-1 infection [51-54]. Further-
more, HIV-1-infected CD34+ HPCs have been detected
in some patients [55,56]. Interestingly, the CD34+ CD4+
HPC subset has an impaired development and growth
when HIV-1 is present. This HPC will then generate a sub
population of monocytes permissive to HIV-1 infection
w i t h  a  l o w  l e v e l  o f  C D 1 4  r e c e p t o r  a n d  a n  i n c r e a s e  o f
CD16 receptor (CD14+ CD16++). This population of
monocyte may differentiate in dendritic cells in tissues
such as lymph nodes [57-59]. It is not yet well understood
whether the abnormalities leading to the generation of
this permissive cell population are due to a direct or anLe Douce et al. Retrovirology 2010, 7:32
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indirect interaction with HIV-1. A further investigation is
needed, since these HPCs generate an infected cell lin-
eage that may spread HIV-1 to sanctuaries.
Mechanisms of HIV-1 latency in the monocyte-
macrophage lineage
Following fusion-mediated entry into the host cell, the
virus is uncoated, the virus genome is reverse transcribed
and the pre-integration complex enters the nucleus where
the proviral DNA is integrated into the host cell genome.
In productive cells, the transcription of the provirus DNA
is regulated by the interplay of a combination of viral and
cellular transcription factors [60-63]. However, cells that
lack or have a low level of HIV-1 expression are also pres-
ent and contribute to viral persistence. It is still contro-
versial whether or not true latency occurs in infected cells
Figure 1 monocyte-macrophage lineage. All cells from the monocyte-macrophage lineage appear to derive from a same progenitor multipotent 
cell, the hematopoietic stem cell (HSC). The HSC, located in the bone marrow, may differentiate either into a myeloid or a lymphoid precursor, setting 
up the divergence between the myeloid (blue) and plasmacytoid (green) lineage. The myeloid precursor is then able to migrate into the blood stream 
and to differentiate into a monocyte. Monocytes migration to specific tissues and their differentiation occur upon a stimulation of a different cytokines, 
interleukins and/or other factors cocktail. Depending to the location, the monocytes become either interstitial dendritic cells, macrophages or micro-
glial cells. Lymphoid precursor runs parallel with the myeloid one, but can directly differentiate into another type of dendritic cell, the plasmacytoid 
dendritic cell.Le Douce et al. Retrovirology 2010, 7:32
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from the monocyte-macrophage lineage. For this reason,
but also to avoid confusion, the word latency will be used
in the following sections, not stricto sensu as previously
defined, but in a larger sense which includes true latency
and low ongoing replication. Contrary to the CD4+ T
cells, in which the mechanisms of the establishment and
the maintenance of true latency have been well described
[64], our knowledge of the molecular mechanisms under-
lying latency in the monocyte-macrophage lineage is
poor. Like in CD4+ T cells, two types of latency occur in
cells from the monocyte-macrophage lineage.
Pre-integration latency
Pre-integration latency is frequently observed in CD4+ T
cells. This form of latency has a very limited contribution
to viral persistence since the half lives of the cells is very
short (1 day). On the contrary, this form of latency in the
monocyte-macrophage lineage may contribute to the for-
mation of reservoirs to a larger extent and may partici-
pate in viral dissemination. This form of latency is
characterized by a poor reverse transcriptase activity and
therefore it is unable to synthesize the provirus DNA.
Various mechanisms are involved in this form of latency,
such as hypermutation of the DNA induced by the
restriction factor APOBEC3, a low level of dNTP pool
and an impaired nuclear importation of the pre-integra-
tion complex associated to a low level of ATP pool [65-
68]. Several reports pointed out that macrophages can
harbor large quantities of unintegrated viral DNA in a
circular form [69,70]. Moreover, these unintegrated DNA
remain stable for up to two months in non dividing mac-
rophages [69]. Interestingly, the accessory viral protein
Vpr is important for viral replication in the monocyte-
macrophage lineage, but not for non dividing CD4+ T-
cells [71]. Indeed, deletion of Vpr decreases transcription
from unintegrated HIV-1 DNA up to 10 times [72]. A
recent report suggests that infected human macrophages
can support persistent transcription from this uninte-
grated DNA [73]. These circular forms of episomal DNA
may therefore account for persistence and expression in
non dividing cells such as macrophages [74].
Post-Integration latency
Post-integration latency occurs once the viral genome has
been reverse transcribed and has been stably integrated
into the host genome. At that moment, the level of tran-
scription is very low with a no or a low level of virus repli-
cation. Mechanisms generating HIV latency in the CD4+
T cells are well described [75,76]. Viral genome integra-
tion into repressive heterochromatin may account for the
establishment of latency in some cases [77]. Transcrip-
tional interference may be responsible for the establish-
ment of HIV-1 latency [78,79] when viral genome
integrates into active euchromatin regions. Several mech-
anisms acting at a transcriptional and post transcriptional
level that maintain the post-integration latency in CD4+
T cells have been described, but it is unknown whether
these are also effective in cells of the monocyte-mac-
rophage lineage. However, several mechanisms generat-
ing HIV-1 post-integration latency have been described
in the monocyte-macrophage, including the lack of, or
dysfunctional Tat, the lack of host transcriptional activa-
tors, presence of host transcriptional repressors, influ-
ence of chromatin environment and host antiviral
processes such as the one based on microRNA (miRNA).
Mechanisms involving Tat transactivation
It has been proposed that restriction of the integrated
HIV-1 genome transcription is due to the lack of Tat
transactivation. The recruitment of the positive tran-
scription elongation factor (pTEFb), which is composed
of two proteins, cyclin T1 (CycT1) and cyclin dependant
kinase 9 (Cdk9) [80-82] makes this transactivation effec-
tive. A lack of transactivation could be due to a low level
of Cyclin T1 expression since its expression is limiting for
p-TEFb function. Indeed, CycT1 is undetectable in undif-
ferentiated monocytes but activated in monocytes-differ-
entiated macrophages [83]. However, CycT1 is not the
only limiting factor involved in the transcriptional inhibi-
tion of HIV-1. The phosphorylation status of CDK9 is
also important as it increases during the differentiation
process of monocytes into macrophages [84].
Mechanisms involving host transcriptional factors
The lack of host transcriptional activators or the presence
of host transcriptional repressors may also explain
latency in these cells. It has been reported that distal LTR
binding sites upstream of the NF-KB binding site are
essential for the efficient transcription in monocytes and
macrophages. In addition to NF-KB and Sp1 binding,
NF-IL6 and/or USF protein binding to the LTR modula-
tory region are essential for HIV-1 transcription [85-87].
In contrast, in microglial cells the core region and the
NF-KB sites are sufficient for transcription [63]. Particu-
larly, Sp1 protein plays an essential role by anchoring
directly or indirectly several cellular transcription factors
to the promoter, such as NF-IL6, CREB and COUP-TF
[88].
The inhibiting form of C/EBPβ/NF-IL6 (LIP), a 16 kDa
inhibitory isoform that is structuraly close to C/EBPγ, is
expressed in macrophages during differentiation. LIP
expression is linked to the suppression of HIV-1 replica-
tion [89]. Although C/EBPβ/NF-IL6 acts as an activator
of HIV-1 transcription, LIP and/or C/EBPγ act as a domi-
nant-negative inhibitor of NF-IL6 mediated transactiva-
tion [88]. Interestingly, this latter mechanism has been
proposed to explain the establishment of transcriptional
HIV latency in microglial cells of a macaque model, pro-
viding the first mechanism of HIV latency in the brain
[90]. The TRAF signaling pathway can activate NF-IL6Le Douce et al. Retrovirology 2010, 7:32
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via the P38-MAPK pathway and is involved in the reacti-
vation of latently infected macrophages [91].
The zinc-finger protein OKT18, which is produced
during HIV-1 infection of macrophages, suppresses HIV-
1 transcription through the viral LTR [92,93]. This pro-
tein exerts its role through the suppression of Tat-medi-
ated HIV-1 LTR activity [94] and through two DNA
binding domains which have been recently identified in
the LTR: The negative-regulatory element (NRE) and the
Ets binding site [93]. It appears that this regulation is cell
type specific since it has been reported that OKT18
e x p r e s s i o n  i s  o n l y  d e t e c t e d  i n  b r a i n  p e r i v a s c u l a r  m a c -
rophages but not in microglial cells [95]. This absence of
OKT18 expression in human microglial cells is due to the
down regulation of YY1 and upregulation of FoxD3 fol-
lowing HIV-1 infection, which leads to a repression of the
OKT18 promoter activity [96]. These results point to
zinc-finger proteins as important modulators of HIV-1
transcription and make them attractive for devising new
drugs to control AIDS [97,98]
HIV-1 transcription is also modulated by proteins of
the Sp1 family which differ in the nature of the Sp protein
bound to the LTR and of the cell type. Indeed, Sp1 and
Sp3 are both expressed in microglial cells, unlike CD4+
T-cells, which express only Sp1. In microglial cells,
although Sp1 acts as an activator of HIV-1 transcription,
the Sp3 protein represses the HIV-1 promoter activity
[99]. Some factors, like IL-6, or hydroxyurea could syner-
gistically reactivate HIV-1 replication in latently
promonocytic cells by increasing the ratio of Sp1/Sp3
[100]. Serpin B2, a serine protease inhibitor induced in
activated monocytes and macrophages during inflamma-
tion is also able to increase the Sp1/Sp3 ratio by inhibit-
ing Rb-degradation, and thus may reactivate latently
infected cells [101].
Importance of the chromatin environment
It is now well established that viral promoter activity
depends on the chromatin environment [102].
Nucleosomes are precisely positioned at the HIV-1 pro-
moter [103,104]. Nuc-1, a nucleosome located immedi-
ately downstream the transcription initiation site,
impedes LTR activity. Epigenetic modifications and dis-
ruption of Nuc-1 are a prerequisite to activation of LTR-
driven transcription and viral expression [102]. Tran-
scriptional repressors, like Myc bind the HIV-1 promoter
and recruit histone deacetylases (HDAC) together with
Sp1 and induce thereby proviral latency [105]. Recently it
was shown that recruitment of deacetylases and methy-
lases on the LTR was associated with epigenetic modifi-
cations (deacetylation of H3K9 followed by H3K9
trimethylation and recruitment of HP1 proteins) in CD4+
T lymphocytes [106]. Some studies suggest that the cellu-
lar signaling pathway which involves the receptor
tyrosine kinase RON could trigger the establishment and
maintenance of HIV-1 latency in monocytic cell lines. A
correlation was found between RON expression and inhi-
bition of HIV-1 transcription. Transcription was affected
at different levels, i.e. chromatin organization, initiation
and elongation [107-109]. The retinoid signaling pathway
may also be involved in the inhibition of HIV-1 reactiva-
tion. The retinoid pathway inhibits both Nuc-1 remodel-
ing and transcription [110].
The transcription factor COUP-TF interacting protein
2 (CTIP2) has been reported [111] to play an essential
role in promoting viral latency in microglial cells. This
factor is a recently cloned transcriptional repressor that
can associate with members of the COUP-TF family
[112]. This factor is expressed in the brain and in the
immune system [113]. We have previously shown that
CTIP2 inhibits replication in human microglial cells
[114,115]. Recently, we have shown that CTIP2 inhibits
HIV-1 gene transcription through recruitment of a chro-
matin-modifying enzyme complex and by establishing a
heterochromatic environment at the HIV-1 promoter in
microglial cells [111]. Indeed, this work suggests that
CTIP2 recruits histone deacetylases HDAC1 and HDAC2
to the viral promoter to promote local deacetylation of
the lysine 9 from histone 3 (H3). In addition, CTIP2 has
also been shown to associate to the histone methyltrans-
ferase SUV39H1, which induces trimethylation of lysine 9
from H3 therefore allowing the recruitment of hetero-
chromatin protein 1 (HP1), heterochromatin formation
and HIV-1 silencing (figure 2). Interestingly, by using a
microarray analysis with a microglial cell line knocked
down for CTIP2, we have shown an up regulation of the
cellular cycle independent kinase inhibitor CDKN1A/
p21waf  (unpublished data). This latter factor has been
recently described as a pivotal facilitator of the HIV-1 life
cycle in macrophages [116,117]. Indeed, HIV-1 infection
activates p21 expression and forces a cell cycle arrest that
is highly permissive for viral transcription in mac-
rophages. We have recently reported that CTIP2 is a key
transcriptional regulator of p21 gene expression [118].
CTIP2 recruited to the p21 promoter silences p21 gene
transcription by inducing epigenetic modifications as
described above for the HIV-1 promoter. This effect indi-
rectly favors HIV-1 latency since activation of p21 gene
stimulates viral expression in macrophages [117]. More-
over, CTIP2 counteracts HIV-1 Vpr which is required for
p21 expression (see the accompanying review from
Ayinde et al for more details regarding the role of Vpr in
macrophage infection). We have suggested that all these
factors contribute together to HIV-1 transcriptional
latency in microglial cells [118]. However, p21 may have
various effects along the replicative cycle of HIV-1; a very
recent report from Bergamaschi et al has described p21
as an inhibitor of the HIV-1 replication [119]. Indeed,
they have shown that FcγR activation can interfere withLe Douce et al. Retrovirology 2010, 7:32
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Figure 2 Functions of CTIP2 in the regulation of HIV-1 gene transcription. CTIP2 (COUP-TF Interacting Protein 2), a transcriptional repressor, has 
been pointed out as an actor of the latency establishment in the macrophage lineage. First, it has been shown that CTIP2 has a direct impact onto the 
HIV-1 LTR promoter by replacing transcriptional activator, such P300 (top left). CTIP2 interacts with Sp1, which is anchored to the LTR, switching nuc-
1 from a transcriptionally active to a repressive state. Following its binding to Sp1, CTIP2 recruits sequentially histone deacetylase (HDAC) 1 and 2, 
which remove acetylation marks from the nuc-1 nucleosome, and then SUV39H1, which add a tri-methylation mark onto the lysine 9 of the histone 
protein H3. As for SUV39H1, it interacts with HP1, a protein stabilizing nuc-1 in a transcriptional closed state. Moreover, CTIP2 is also able to indirectly 
repress HIV-1 gene transcription. Indeed, CTIP2 can counter the action of the viral protein Vpr. One of the roles of Vpr is to induce a cell cycle arrest 
through activation of the p21 gene. Sp1-mediated recruitement of Vpr to the p21 gene promoter increases the production of the p21 protein, a cell 
cycle regulator. Consequence of such block in cell cycle is an enhancement of the viral transcription. The binding of CTIP2 to the p21 promoter forces 
Vpr release, HDACs and SUV39H1 recruitment, HP1 association and p21 gene silencing.Le Douce et al. Retrovirology 2010, 7:32
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the pre-integration step of the HIV-1 cycle and is associ-
ated to the induction of p21 expression. This role of p21
as an inhibitory factor in macrophages has also been
reported for other Lentiviruses such as SIVmac and HIV-
2 [119]. As discussed in this latter report and in the
accompanying review (Bergamaschi and Pancino), p21
might have different effects on HIV-1 infection of mac-
rophages depending on the targeted viral life cycle step
and therefore on the time since infection.
An original post transcriptional mechanism involved in 
latency: the microRNA
The host antiviral processes using microRNA (miRNA)
as a defense mechanism are now considered as funda-
mental for regulation of animal and plant gene expression
[120]. Indeed miRNA, 19-25 nucleotide long non-coding
RNAs, are involved in various biological processes in
eukaryotic cells [121,122]. The miRNAs interact with a
complementary sequence in the 3'-UTR of target
mRNAs, that leads either to mRNA degradation, or more
often to translational inhibition [122]. It has been shown
t h a t  m i R N As  a r e  i n v o l v e d  a s  w e l l  i n  t h e  r e gu l a t i o n  o f
virus expression [123]. These processes are manipulated
or quenched by HIV-1, and this favors the establishment
and maintenance of latency [124]. Recently, it was shown
that miRNAs regulate the expression of the histone
acetyltransferase Tat cofactor PCAF, and HIV replication
[125]. Moreover, an enrichment of miRNAs in clusters
has been observed only in resting CD4+ T cells and not in
active CD4+ T cells [126], suggesting that these miRNA
clusters inhibit HIV replication and therefore contribute
to HIV latency in resting primary CD4+ T cells. A similar
mechanism, based on cellular miRNA, has also been
described in circulating monocytes [127]. In another
recent report Sung & Rice have identified a miRNA (miR-
198) that is strongly down-regulated when monocytes are
induced to differentiate. Moreover, they have shown that
this miRNA restricts HIV-1 replication through the
repression of CycT 1 expression [128]. This result con-
firms previous observations that translation of CycT1
mRNA is inhibited in monocytes [129]. Identification of
additional miRNAs involved in the repression of host
and/or viral factors that could be involved in HIV-1
restriction are needed. Altogether, these data indicate
that miRNA are crucial in promoting HIV-1 latency and
suggest also that a manipulation of miRNAs could be use-
ful in therapies aiming to purge reservoirs [130].
Influence of the microenvironment in establishing latency
Finally, it has been proposed that the establishment of
latently infected macrophages occurs in a suppressive
microenvironment made of apoptotic cells [131]. Apop-
totic cells induce an inhibition of HIV-1 transcription in
the infected macrophages by a signal transduction which
involves ELMO. This molecule is indeed involved in the
phagocytosis of apoptotic cells [131].
Mechanisms of HIV-mediated apoptosis resistance 
in the monocyte-macrophage lineage
Another strategy developed by the virus in order to per-
sist in infected cells is to render them resistant to apopto-
sis.
The NF-kB pathway
Several reports have pointed out that NF-kB activity pre-
vents cells to undergo apoptosis [132,133] The pathway
involving NF-kB is activated upon HIV-1 infection in
monocyte cells and in primary macrophages [134] (see
also the accompanying review from Herbein et al). It has
been proposed that TNFα-induced NF-kB activity might
be involved in the inhibition of apoptosis and the survival
of monocytes and macrophages even if Tumour Necrosis
Factor alpha (TNFα) is best known as a pro-inflamma-
tory mediator capable to induce apoptosis. Persistent
HIV-1 infection of macrophages results in increased lev-
els of the transcription factor nuclear factor kappa B (NF-
κB) in the nucleus secondary to increased IκBα, IκBβ, and
IκBε degradation, a mechanism postulated to regulate
viral persistence [135,136]. NF-κB is involved in the resis-
tance to TNF-induced apoptosis that might result in a
decreased susceptibility to apoptosis of macrophage ver-
sus T cells in the context of chronic immune activation
like in HIV-1 infection. This indicates clearly that HIV-1
can manipulate the apoptotic machinery to its advantage.
Moreover, HIV-1 can induce a dual regulation of the anti-
apoptotic protein Bcl-2, resulting in persistent infection
of monocytic cells [137]. HIV-1 infection first results in a
decrease of Bcl-2 and thioredoxin, permitting an initial
boost of replication. Then, as the synthesis at the tran-
scriptional level proceeds, replication is negatively con-
trolled by Bcl-2 to reach a balance characterized by low
virus production and higher Bcl-2 and thioredoxin levels
resulting in low but sustained viral production compati-
ble with cell survival [137,138]. Recently, the absence of
apoptosis in HIV-1-infected primary human mac-
rophages has been reported to correlate with an increase
in anti-apoptotic Bcl-2 and Bcl-XL proteins and a
decrease of pro-apoptotic Bax and Bad proteins [139].
The role in apoptosis of viral proteins is often dual
The protein Nef is a regulating protein expressed early
and abundantly throughout the course of HIV-1 infec-
tion. This protein has dual effects depending on the stage
of infection. In the early stage, Nef contributes to the con-
stitution of reservoirs with sustained virus production. It
mimics the action of TNFα with subsequent activation of
NF-kB and MAPK [140,141]. In latter stages, it is
involved in the inhibition of apoptosis in infected cells by
blocking TNF-mediated apoptosis [142-144]. The Nef
protection to the HIV-1-induced apoptosis correlated
with the hyper-phosphorylation and consequent inacti-Le Douce et al. Retrovirology 2010, 7:32
http://www.retrovirology.com/content/7/1/32
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vation of the pro-apoptotic Bad protein [143]. Finally, Nef
is also involved in the blockade of p53-mediated apopto-
sis [145]. Therefore the Nef anti-apoptotic effect could be
a relevant part of the mechanism of the in vivo establish-
ment of the HIV-1 macrophage reservoirs. Macrophage
express 10-times lower numbers of cell surface CD4 than
CD4+ T cells [146], and therefore might be less suscepti-
ble to HIV-1 superinfection. Since high levels of cell sur-
face CD4 on HIV-infected cells reportedly induce a
dramatic reduction in the infectivity of released virions
by sequestering the viral envelope by CD4 [147], low lev-
els of CD4 on the cell surface of macrophage might
favour the release of infectious virions from the infected
cell, and thereby could optimize transmission of virions
to the cells present in the vicinity. Third, the viral life
cycle of HIV-1 is 6-times slower in primary macrophage
than in primary T cells due to a slower reverse transcrip-
tion process, suggesting that the rate of virion production
might be lower in macrophage than in CD4+ T cells,
thereby allowing macrophage to form long-lasting virus
reservoirs [148,149].
Tat and gp120 have also dual effects on apoptosis
depending of the cell type. In the central nervous system,
HIV-1 triggers apoptosis in neurons. This is also seen
when neurons are exposed to extracellular Tat or gp120
[150]. On the other hand, microglial cells, the CNS resi-
dent macrophage, do not undergo apoptosis upon HIV-1
infection or following exposure to extracellular viral pro-
teins such as Tat or gp120 [151-153]. Tat-mediated resis-
tance to apoptosis in microglial cells is due to the
activation of the PI-3-K/AKT cell survival signaling path-
way. The protein Tat also decreases the activity of p53.
The protein Tat has also been shown to mediate apopto-
sis resistance by up regulating Bcl-2. This anti-apoptotic
factor inhibit TNFα related apoptosis-induced ligand
(TRAIL mediated apoptosis) [154]. This combined action
of Tat will therefore favor long term cellular survival
observed in microglial cells throughout the course of
HIV-1 infection [152].
Over-expression of CTIP2, described as an anti-apop-
totic factor [155], in microglial cells leads to a repression
of p21 expression [118]. This is partly due to the inhibi-
tion of the p53 activity on p21 transcription and also to
the fact that CTIP2 counteracts Vpr. This latter protein
has been shown to trigger apoptotic events in infected
lymphocytes and in neurons [156-158]. Taken together,
the data suggest that CTIP2 might be involved in the
apoptosis resistance of microglial cells, besides its role in
the establishment and maintenance of HIV-1 latency.
Some investigators have shown that p21 transcription is
slightly increased in monocytes recovered from chroni-
cally-infected patients and is associated with an anti-
apoptosis signature [159]. The apparent discrepancy in
the role of p21 in apoptosis in monocytes versus micro-
glial cells needs to be clarified. It might arise from the
dependence of the activities of p21 on the cell type, sub-
cellular location, expression level and phosphorylation
status. Moreover, p21 expression is regulated by both
p53-dependent and p53-independent mechanisms. An
increase in p21 expression mediated by Fcγ R activation
in macrophages was not due to an induction of p53 since
its silencing did not block p21 induction by Immune
Complexes [119]. It should be noted that it is not clear
whether p21 is an oncogene [160] (which could be
involved in the inhibition of apoptosis) or an anti-onco-
gene [161] (which could be involved in the induction of
apoptosis).
The protein gp120 produced by monocyte-mac-
rophages inhibits TRAIL-mediated cell death by inducing
the expression of macrophage-stimulating factor (M-
CSF). This envelope protein also up-regulates expression
of several anti-apoptotic genes such as Bfl-1 and Mcl-1
[162]. A stable signature of anti-apoptosis, comprising 38
genes including p53, MAPK and TNF signaling networks
has also been identified from circulating monocytes of
HIV-1 infected patients [159]. CCR5 co-receptor bound
by HIV-1 can lead to apoptosis resistance in monocyte
cultures. A recent report has also stressed the central role
of CCR5 during HIV-1 infection [163]. This paper
described a case of a HIV-1 positive patient, who received
bone marrow transplantation for leukemia. In the follow-
up study there was no evidence of the virus in the blood-
stream even after 20 months. Myeloablation and T cells
ablation were suggested to favor the elimination of the
long-lived reservoirs. Indeed, transplantation was done
with cells from a homozygous donor for mutation in the
HIV-1 co-receptor CCR5. This mutation is well known to
be associated with resistance to HIV-1 infection. There-
fore development of new molecules to inhibit CCR5 core-
ceptor function will be a great challenge in the next years.
It will be also interesting to investigate whether the inter-
action between CXCR4 co-receptor and HIV1 could also
trigger apoptosis resistance. Apart from the critical role
CCR5 plays in maintaining HIV-1 infection, this study
also raises the possibility that the main target to cure the
patients from AIDS are the peripherical circulating cells
including the monocytes (and by the way the infected
HPCs). Indeed, whole-body irradiation leading to com-
plete remission of acute myeloid leukemia will mainly tar-
get radiosensible cells such as HPCs and peripherical
circulating cells. The fact that no virus has been detected
at month 20 of follow-up, might suggest that reservoirs in
sanctuaries could not sustain viral replication alone.
However, the importance of these reservoirs in the physi-
ological context of infected WT-CCR5 patients should
not be neglected.Le Douce et al. Retrovirology 2010, 7:32
http://www.retrovirology.com/content/7/1/32
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Discovery of a new anti-apoptotic mechanism based on 
miRNA
Finally, a new mechanism has been proposed that protect
cells from apoptosis and therefore extend the lifespan of
infected cells. This mechanism is based on the suppres-
s i o n  o f  t h e  c e l l ' s  R N A i  a c t i v i t y  b y  s y n t h e s i s  o f  a  T A R
miRNA, a small hairpin RNA. This RNA is capable to
sequester the miRNA processing machinery of the cell
and therefore impedes the functioning of cellular antiviral
miRNAs [164]. Moreover, this TAR miRNA has also been
shown to be involved in the down regulation of the
expression of several proteins related to apoptosis [165].
Our knowledge of the mechanisms involved in apopto-
sis resistance is far from complete. The diversity of strate-
gies used by HIV-1 to manipulate the apoptotic pathway
emphasizes the capacity this virus possesses to survive in
its host. We note that mechanisms involved in apoptosis
resistance, at least the mechanisms involving the TNF-
signaling pathway, are also involved in virus production.
It seems that the nature of this reservoir is rather differ-
ent from the latent reservoir. The therapeutical implica-
tions are therefore important since stimuli such as
phorbol esters will not be suitable to purge the reservoir.
Indeed, this treatment will reactivate the expression of
HIV-1 in latent reservoir but may increase the resistance
to apoptosis in viral reservoir that exhibit a sustained
production of virions. The survival of viral reservoirs is of
great importance since it is also an obstacle to HIV-1
eradication. The mechanisms underlying this apoptosis
resistance are essential for devising new and original
therapeutic strategies to purge the reservoirs, but are far
from being completely known.
Implications for therapy
The introduction of HAART in 1996 has greatly
improved survival, but it has been unable to eradicate the
virus from latently infected reservoirs. A principle cause
may be that besides the best characterized cellular reser-
voir of memory CD4+ T-cells there are other reservoirs,
such as the monocyte-macrophage reservoir. Moreover,
these cells are often found in tissue sanctuary sites, like
the brain, that are protected from drug penetration [166-
168]. Furthermore, several reverse transcriptase inhibi-
tors are ineffective in chronically infected macrophages
[34] and protease inhibitors have significantly lower
activities in these cells compared to lymphocytes [169].
The emergence of multidrug resistant viruses has been
reported in an increasing number of patients receiving
HAART [110,170,171]. Finally, the nature of the reser-
voirs (latent reservoir with no or low virus replication
versus productive reservoir which are resistant to apopto-
sis) has to be taken into account. These considerations
(existence of several reservoirs, tissue-sanctuary sites and
multidrug resistance) encourage the search for new and
original anti HIV-1 treatment strategies. New methods
s h o u l d  be  d ev e l o ped  w h i c h  ta r g e t  ea c h  o f  t h e se  r e se r -
voirs. We believe that eradication of the virus could be
achieved by specifically purging targeted reservoirs and
concomitantly eliminating the virus by a reinforced
HAART. Another way to control HIV-1 replication is to
re-inforce the latency status by using transcriptional
inhibitors.
Use of transcriptional inhibitors to control HIV-1 
progression
At present the therapy of HIV-1-infected patients is
based on a combination of HIV gp41, reverse tran-
scriptase and protease inhibitors. We believe that new
drugs should target other steps of the HIV-1 cycle. For
example, they could be directed against proteins involved
in the transcription of the inserted virus genome. Tat has
a critical role in transcription, and constitutes a major
target in therapeutic intervention in the HIV replicative
cycle [172-174]. Moreover, drugs could be designed to
target cellular cofactors involved in the activation of tran-
scription. This strategy should be able to by-pass drug-
resistance which arises with viral proteins. Therefore,
ways to synthetize drugs which interfere with HIV-1 rep-
lication in monocyte-macrophage should be devised
[175]. Several transcriptional inhibitors already charac-
terized such as C-terminally truncated STAT5, Staf 50,
Prothymosin α and thioredoxin reductase [176-179]
could be used for controlling viral expression in the
human macrophages. Inhibition of the NFAT5-LTR inter-
action by using small interfering RNA is also promising
since it suppresses HIV-1 replication in primary mac-
rophages and therefore progression of AIDS [180]. The
discovery that only macrophages are able to repress HIV-
1 transcription and replication in response to Il10 need
further investigation since we could specifically control
HIV-1 expression in these cells [129,181]. The demon-
stration that treatment of HIV-1 infected lymphocytes
with the O-GlcNAcylation-enhancing agent glucosamine
repressed viral transcription opens the way to metabolic
treatment [182]. This treatment might work in the mono-
cyte-macrophage lineage since this chemical compound
affects Sp1 and therefore inhibits the activity of the LTR
promoter. According to several reports, OKT18, a zinc-
finger protein, can reduce HIV-1 replication in human
macrophages by the suppression of Tat-induced HIV-1
LTR activity [93,183]. New approaches based on engi-
neered transcription factors are now emerging with zinc
finger protein as an attractive candidate for antiretroviral
therapy since their binding to HIV-1 LTR in a sequence
specific manner is associated with the repression of LTR
activity [97,98]. Interestingly, zinc-finger protein can
influence the chromatin compaction and nuclear organi-Le Douce et al. Retrovirology 2010, 7:32
http://www.retrovirology.com/content/7/1/32
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zation through regulation of proteins involved in epige-
netic regulation [98].
Finally, new drugs must be designed with properties
that allow them to penetrate tissue-sanctuary sites such
as the brain [166].
Strategies based on virus reactivation from latent 
reservoirs
Recently, a new and original strategy has been proposed
to eradicate the virus from infected patients. The main
idea is to facilitate the reactivation of viruses from latent
reservoirs, which are then destroyed by HAART (figure
3 ) .  M a n y  f a c t o r s  h a v e  b e e n  i n v o l v e d  i n  r e a c t i v a t i o n
including physiological stimuli, chemical compounds like
phorbol esters, histone deacetylase inhibitors, p-TEFb
activators, and some activating antibodies (antiCD3).
Many eradication protocols passed preclinical studies [2]
but to date all failed in clinical trials. Some protocols
failed due to the potential toxicity of treatments based on
non specific cell activation such as IL2 [184]. The recent
discovery that an alternatively spliced form of the cellular
transcription factor Ets-1 can activate latent HIV-1 in an
Figure 3 Pharmaceutical approaches of the potential reactivation pathways on latently integrated HIV-1 genome. Multiple ways of reactiva-
tion are possible to occur to re-initiate the HIV-1 transcription. Extern signals, such as TNF-α, can trigger the activation of transcriptional activator, like 
the heterodimer p50/p65. In the mean time, host protein balance may change, leading to higher availability of transcriptional activators. For instance, 
miRNAs regulates the rate of PCAF, a coactivator produced by the host cell (green arrow - Multiple potential reactivation pathways). There are some 
critical steps in this process that may be targeted to reactivate or hinder the latency establishment (Red boxes). HDAC inhibitors (HDACi) may prevent 
the formation of heterochromatin; Prostratin induces the IKK activation, which provokes the activation of transcriptions factors; HMBA increases the 
pTEFb release from the inactive stock; it is possible to reverse the miRNAs negative impact on the mRNAs of transcriptional activators and/or CycT1 
through specific siRNAs.Le Douce et al. Retrovirology 2010, 7:32
http://www.retrovirology.com/content/7/1/32
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NF-KB independent manner has highlighted the thera-
peutic potential of cellular factors for the reactivation of
latent HIV-1 [185]. Future eradication protocols should
use a combination of drugs targeting all the viral silencing
mechanisms identified to reactivate HIV-1 from latently-
infected cells. A protocol with a similar approach gave
promising results. In this study, the association of a
HDAC inhibitor or a DNA methylation inhibitor with
prostratin (phorbol ester that stimulates protein kinase C
activity) proved to have a synergistic effect on the activa-
tion of HIV-1 expression [186,187].
Strategies based on increasing apoptosis susceptibility
Increasing the susceptibility of the infected cells to apop-
tosis is also of great interest. Essentially, the HIV-1 pro-
teins Tat, Nef and the envelope protein gp120 should be
targeted, as these proteins have a crucial function in dif-
ferent steps of the virus cycle and also in the acquired
resistance to apoptosis. A better comprehension of mech-
anisms involved in resistance to apoptosis has also
allowed to devise drugs against host factors which render
cells susceptible to die. For example, molecules which
interfere with the chemokine receptor CCR5 are promis-
ing since these molecules are both involved in virus entry
and in apoptosis resistance. Several CCR5 antagonists are
already used in clinical trials [188,189]. A chemothera-
peutic drug, Imatibib, restored apoptotic sensitivity of
HIV-1 macrophages through the inhibition of the activity
of the pro-survival cytokine macrophage colony-stimu-
lating factor (M-CSF) [162]. Finally, several AKT inhibi-
tors including Miltefosine are also promising molecules
for targeting long-lived viral reservoirs [190].
A dramatic reduction of monocyte-macrophage reser-
voirs might be achieved by strategic interventions target-
ing both the resistance of infected cells to apoptosis and
the reactivation of latently-infected cells associated with a
reinforced antiretroviral therapy.
Conclusion
Cells from monocyte-macrophage lineage are an ideal
reservoir for HIV-1. This is due to several features of
these cells including long lifespan, absence of direct cyto-
pathic effect, apoptosis resistance of infected cells, exis-
t e n c e  o f  l a t e n t l y  i n f e c t e d  c e l l s  ( w i t h  l o w  o r  n o  v i r u s
expression) and their localization in sanctuaries. The
purging of this reservoir is therefore crucial since it con-
stitutes one of the major obstacles to HIV-1 eradication
from infected patients. A drastic reduction of this reser-
voir might be achieved by the development of new and
original therapies which target specifically all the reser-
voirs, including the monocyte-macrophages. These treat-
ments might not lead to a complete eradication of HIV-1
but there is hope that a drastic reduction could be
achieved with levels of expression comparable to those in
elite non progressors patients who remain asymptomatic
without an antiretroviral therapy.
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